Utama › Penyakit Paru Interstisial › South Carolina
Kajian klinikal Penyakit Paru Interstisial di South Carolina
14 kajian untuk Penyakit Paru Interstisial sedang mencari peserta di lokasi di South Carolina.
Bandar di South Carolina
Teks kajian rasmi (Bahasa Inggeris)
FIBRONEER-ACT: A Study to Test Whether Nerandomilast Helps People With Fibrosing Interstitial Lung Disease at Risk for Disease Progression
- Lowcountry Lung and Critical Care, Charleston
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 1 Okt 2026 · NCT07540988A Study to Test Whether Nerandomilast Can Help Slow Down Changes in the Lung in People With a Family History of Pulmonary Fibrosis
- Medical University of South Carolina, Charleston
Mengambil pesertaFasa 3
Umur 40 ke atas · Semua jantina · Dikemas kini 30 Sep 2026 · NCT07201922LAM-001 for the Treatment of Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
- MUSC, Charleston
- Velocity Clinical Research, Spartanburg
Mengambil pesertaFasa 2
Umur 18 hingga 80 · Semua jantina · Dikemas kini 29 Sep 2026 · NCT05798923SUPPORT-T in Patients With Progressive Pulmonary Fibrosis and Their Caregivers
- Medical University of South Carolina, Charleston
Mengambil peserta
Umur 18 ke atas · Semua jantina · Dikemas kini 11 Sep 2026 · NCT07269262A Phase 2 Study of LTI-03 in Patients With Idiopathic Pulmonary Fibrosis
- Medical University of South Carolina, Charleston
Mengambil pesertaFasa 2
Umur 40 ke atas · Semua jantina · Dikemas kini 4 Sep 2026 · NCT06968845Multi-site Study of the Clinical Impact of an AI-assisted Approach to Referring Patients With Interstitial Lung Disease for Diagnostic Evaluation of Pulmonary Hypertension
- Medical University of South Carolina, Charleston
Mengambil peserta
Umur 18 ke atas · Semua jantina · Dikemas kini 2 Sep 2026 · NCT06911632A Study of Mosliciguat in Combination With Inhaled Treprostinil in PH-ILD
- Clinical Research Site, Charleston
Mengambil pesertaFasa 2
Umur 18 hingga 85 · Semua jantina · Dikemas kini 2 Sep 2026 · NCT07333183DeciPHer-ILD: A Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
- AnMed Health, Anderson
- Medical University of South Carolina, Charleston
Mengambil pesertaKajian pemerhatian
Umur 18 ke atas · Semua jantina · Dikemas kini 26 Ogo 2026 · NCT06388421Platform Clinical Study for Conquering Scleroderma
- Medical University of South Carolina (MUSC), Charleston
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 18 Ogo 2026 · NCT06195072Idiopathic Pulmonary Fibrosis and Interstitial Lung Disease Prospective Outcomes Registry
- Medical University of South Carolina, Charleston
Mengambil pesertaKajian pemerhatian
Umur 21 ke atas · Semua jantina · Dikemas kini 12 Ogo 2026 · NCT01915511Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)
- Medical University of South Carolina-Nexus, Charleston
- Prisma Health Pulmonology-Richland, Columbia
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 13 Jul 2026 · NCT05943535An Open-Label ProSpective MultiCENTer Study to Evaluate Safety and Tolerability of Dry Powder Inhaled Treprostinil in PH
- Medical University of South Carolina, Charleston
Mengambil pesertaKajian pemerhatian
Umur 18 hingga 80 · Semua jantina · Dikemas kini 26 Jun 2026 · NCT06129240Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis
- Bogan Sleep Consultants, LLC, Columbia
Mengambil pesertaFasa 2
Umur 40 ke atas · Semua jantina · Dikemas kini 12 Nov 2025 · NCT05975983Study to Evaluate the Efficacy, Safety, and Tolerability of Efzofitimod in Patients With Systemic Sclerosis (SSc)-Related Interstitial Lung Disease (ILD) (SSc-ILD)
- aTyr Investigative Site, Charleston
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 7 Mei 2025 · NCT05892614Daripada ClinicalTrials.gov, data diperoleh pada 5 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.